WuXiTecan-2

Shanghai – October 15, 2026 -- WuXi XDC (2268.HK) has won "Best CDMO" at the 2026 World ADC Awards for the fourth consecutive year and "Best CRO" for the second, making it the only contract research, development and manufacturing organization (CRDMO) to take both titles two years running.

WuXi XDC reports record 51 new iCMC projects in first half of 2026

According to the company's 2026 interim results, WuXi XDC had more than 810 global clients as of June 30, 2026. Fifteen of the top 20 pharmaceutical companies by revenue are among its partners. The company has helped clients submit more than 160 IND applications and now holds 328 iCMC projects. The 51 signed in the first half of 2026 are a record.

Headcount exceeds 3,600, and more than 50% of employees hold a master's degree or higher.

Shanghai – September 20, 2026 -- WuXi XDC Cayman Inc. (2268.HK) has out-licensed its proprietary WuXiTecan-2 payload-linker technology platform to Ona Therapeutics under an exclusive global agreement targeting a single antibody-drug conjugate (ADC) candidate.

Deal structure includes upfront payment, milestones and tiered royalties

The agreement grants Ona Therapeutics exclusive global rights to develop an ADC candidate using WuXi XDC's WuXiTecan-2 platform. The total potential deal value comprises an upfront payment plus development, regulatory and sales milestone payments, with WuXi XDC also eligible for tiered royalties on net sales once the resulting product reaches commercialization. WuXi XDC will additionally provide chemistry, manufacturing and controls (CMC) development and manufacturing support through its integrated ADC CRDMO platform.